E. Ohman J:or Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

E. Ohman J:or Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$592K	Hold	3,512	–	–	0.01%	387
2026 Q1	$463K	Hold	3,512	–	–	0.01%	414
2025 Q4	$498K	Buy	+3,512	New	+$509K	0.01%	425
2022 Q3	–	Sell	-5,000	Closed	-$487K	–	441
2022 Q2	$487K	Buy	5,000 +3,300	+194%	+$305K	0.02%	355
2022 Q1	$159K	Buy	+1,700	New	+$144K	0.01%	421
2021 Q4	–	Sell	-3,900	Closed	-$374K	–	476
2021 Q3	$374K	Hold	3,900	–	–	0.01%	427
2021 Q2	$380K	Buy	3,900 +2,200	+129%	+$211K	0.01%	437
2021 Q1	$165K	Buy	+1,700	New	+$178K	0.01%	438

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

E. Ohman J:or Asset Management's NBIX Position: Q2 2026 in Review

E. Ohman J:or Asset Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 3,512 shares worth $592K. The position accounts for 0.01% of the portfolio, ranked #387.

E. Ohman J:or Asset Management first reported a position in NBIX in Q1 2021 and has held it in 8 quarters since. 439 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

E. Ohman J:or Asset Management held 3,512 shares of Neurocrine Biosciences worth $592K as of Q2 2026.
E. Ohman J:or Asset Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 0.01% of E. Ohman J:or Asset Management's portfolio in Q2 2026, its #387 holding.
E. Ohman J:or Asset Management first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 8 quarters since.
439 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on E. Ohman J:or Asset Management's 13F filing for Q2 2026, filed 10 Jul 2026.